Tagged with HE

Pharma The Vice-Chairman of the Public Health Enhancement Fund talks about how the shortage of medical doctors and the fight against TB, HIV and AIDS in South Africa led the health Minister and the private health sector to create a public health enhancement fund and how the private sector is pulling resources…

pharma The Director of the CNCR and the person in charge of the industrial sector, talk about the fragmented nature of French clinical research funding, why when it comes to boosting France’s attractiveness as a clinical research destination, funding is the number one issue for hospitals and reveals how the number…

France The President of France’s Association for CROs (AFCROs) discusses the issues surrounding France’s clinical research sector and the actions that both the public and private sector need to take to maintain their competitiveness. He also discusses his company’s recent merger with Biostatem and their mission to internationalize. While France remains…

Netherlands The future of drug development is about interacting, sharing and collaborating. The President and CEO of Genmab, an international biotechnology company focusing on differentiated antibody therapeutics for the treatment of cancer, discusses the company’s most recent milestones as well as how it is fostering a collaborative model based on partnerships.…

France The Head of the Department of Medicine at the Faculty of Health Science at the University of Cape Town reveals how their role is not only in training people to be technically competent, but to produce the next generation of thinkers, researchers and innovators, how The Lancet report, produced by…

France The president of Gedeon Richter France and CEO of PregLem, a Swiss-based biotech company acquired by Gedeon Richter in 2010, discusses the exciting synergies that have emerged from this partnership in the past few years, her perspective on market access in France and the challenges and opportunities she has faced…

pharma The CEO and founder of ModiQuest discusses how, with its unique, fully-integrated antibody generation and development platform, the company is developing antibodies for potentially groundbreaking therapies for the prevention and treatment of rheumatoid arthritis and growing its already well-established CRO arm serving clients from around the world. Could you introduce…

pharma The general manager of Ferring South Africa, Mercia Van Zyl discusses the company’s ambitious plans for the future under the slogan ‘People come first’, the placement of fertility under the nation’s therapeutic priorities, and how the company is contributing to an overall better healthcare system in the country. Could you…

pharma CEO of Pantarhei since its inception in 2001, Herjan Coelingh Bennink outlines the company’s vision to develop new applications for existing compounds in the fields of women’s health and oncology with therapies with real medical advantages including a contraceptive pill which does not increase the risk of thrombosis and improved…

pharma The CEO of BioConnection, the leading contract services and manufacturing organization for the development and production of injectable (bio)pharmaceutical products, explains how —thanks to flexibility and quality-driven mentality —the company helps small and medium biotech companies and universities make their products reality. This year BioConnection celebrates its tenth anniversary and…

pharma The Netherlands provides a flourishing environment for biotech to grow. The vice president for European operations at Kite Pharma discusses how biotech start-ups can find their path to success and how Kite Pharma is looking at new innovative therapies for cancer treatment. Before joining T-Cell Factory, later acquired by Kite…

pharma IMS Health helps clients reach the top of the mountain by providing them with the necessary intelligence to take actionable steps. Manuel Voll, Senior Principal for Northern Europe shares his perspective about the Dutch healthcare and life sciences market, the challenges it poses and what companies can expect for the…